Fluence leading the way in growing niche market
In a world where there is an increasing focus on establishing a reliable supply of healthy water, Fluence Corporation Ltd (ASX:FLC) is having outstanding success.
Fluence has a strong stable of proprietary products which are used in the treatment of decentralised water, wastewater and reusable water.
The company’s products and services are well sought after, and as recently as yesterday the group was awarded a sizeable contract by the federal government of Ivory Coast for the supply of a 150,000 cubic metre per day surface water treatment plant.
This project valued at €165 million will provide potable water to Abidjan, the country’s largest city with a population of 4.7 million.
The scope of work under the contract includes water intake, water treatment, bulk water piping, water towers and infrastructure.
The plant will include cutting-edge integration of proven technologies, including smart intake, various separation and membrane systems, advanced oxidation, biological filtration and sludge treatment.
The advanced multiple barrier design (ensuring water quality according to World Health Organisation standards) is an environmentally sound water treatment process that allows the flexibility to optimise operating costs in various feed qualities.
The design combines Fluence’s suite of water treatment technologies and demonstrates the company’s expertise in areas of water biology, chemistry and its range of treatment processes.
Such is the adaptability of Fluence’s technology that the end-product will be produced by treating water from Lagune Aghien, Ivory Coast’s largest freshwater reserve near Abidjan, which is dense with algae and other contaminants.
In relative terms, the size of this contract (US$187 million) is an extremely important development for the group considering the company’s full-year revenues for the 12 months to December 31, 2018 were US$105.6 million.
The contract is expected to generate revenues of US$20 million in 2019 and US$80 million in revenue in 2020, with the remainder in 2021.
Recurring revenues provide earnings predictability
Fluence has been focused on building recurring revenues by incorporating facility management into contracts.
The company has started to build a meaningful recurring revenue base, with secured average annual recurring revenue of US$14.7 million at 31 December 2018.
Importantly, Fluence has been invited by the Ivory Coast government to bid for an operating and maintenance contract, which could provide further recurring revenue.
With the company continually expanding its global presence, its revenue and profit growth momentum as illustrated below looks set to continue.
Management recently reaffirmed its underlying earnings guidance for 2019, projecting that the company will move to profitability by the December quarter.
Expansion into China
The expansion of Fluence into China, both through sales and manufacturing facilities, strongly positions the company to participate in the planned improvement in China’s rural wastewater treatment quality.
The Chinese Government’s current five-year plan is targeting, and provides finance for, an increase in rural wastewater treatment to reach Class 1A effluent discharge.
With approximately 10% of rural wastewater currently treated and the five-year plan’s target to reach 70% treatment of wastewater in China, Fluence’s Smart Packaged AspiralTM system featuring MABR technology is the lowest cost treatment alternative available in the decentralised market, and simultaneously guarantees to consistently reach Class 1A effluent discharge standards.
A successful demonstration plant with Chinese partner Hubei ITEST, enabled the execution of an exclusivity agreement in October with anticipated AspiralTM sales estimated at a minimum of US$45 million over the next three years.
The first two contracts under this partnership were booked in December with a total of 35 AspiralTM units to be deployed.
In November 2018, Fluence announced a new partnership with environmental EPC firm Zhongzi Huaze and executed a multi-unit AspiralTM order.
Six AspiralTM units were delivered in December 2018 and commissioned in January 2019 - the first for Fluence in Jilin Province.
Fluence is actively quoting SUBRE (submerged MABR) projects for potential clients in China and in other key markets and the group continues to focus on the full commercialisation of the product in the first half of 2019.
An example of SUBRE is shown below.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.